Articles tagged with Long Covid
A recent study published in eClinicalMedicine found that a combination of amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms. The researchers assessed symptom diaries and health-related quality of life questionnaires, but saw no significant difference between treatment and placebo groups.
Researchers at Brigham and Women's Hospital found that people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood compared to those without long COVID symptoms. This persistent infection could explain some of the long COVID sufferers' symptoms, suggesting a potential treatment target.
Damage to the brainstem, the brain's control centre, is behind long-lasting physical and psychiatric effects of severe Covid-19 infection. Researchers used ultra-high-resolution scanners to observe the damaging effects of Covid-19 on the brain, finding inflammation in key regions associated with breathlessness, fatigue and anxiety.
A small clinical trial found that low-dose lithium aspartate is ineffective for long COVID symptoms, but a dose-finding study suggests higher doses may be effective in reducing fatigue and brain fog. Researchers are calling for further studies to explore the potential of lithium aspartate at higher dosages.
Researchers found that wearable fitness technology can provide greater control and certainty for Long COVID sufferers, but also anxiety and uneasiness. Participants used data from their watches to regulate energy expenditure and understand symptoms, leading to a degree of control over the disease and body.
Long COVID patients face numerous barriers and frustrations in receiving care, yet express a desire for collaborative treatment planning. The study highlights the need for improved communication and collaboration between patients and healthcare professionals.
A new long-term study found that memory T cells can be established and maintain key features to fight off subsequent infections of newer strains, providing potential insight into rapid recovery from COVID. The study's findings are important for understanding how the body responds to COVID-19.
Researchers have proposed a novel treatment strategy for post-acute infectious syndromes (PAIS), including Long COVID. The multimodal approach combines pharmacological interventions like metformin and low-dose naltrexone with physical therapies like extracorporeal apheresis.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
A study published in Nature found that immune cells called CD8+ T cells prevent lung healing and repair post-infection, leading to pulmonary fibrosis. This discovery may lead to new therapeutic treatment options for patients with long COVID.
A new study from the University of Kansas reveals that individuals with pre-existing disabilities are more than twice as likely to develop long COVID. The research found that chronic illnesses and mental illness/psychiatric disabilities were the most common types of disabilities among those experiencing long COVID.
A new study published in JRSM Open found that pain is the most prevalent and severe symptom reported by individuals with long Covid, affecting 26.5% of participants. Demographic factors such as age, gender, ethnicity, education level, and socioeconomic status significantly impact symptom severity.
Researchers discovered that the blood coagulation protein fibrin causes unusual clotting and inflammation in COVID-19, suppressing the body's ability to clear the virus. A promising therapeutic strategy has been identified, targeting fibrin to combat these deleterious effects.